CA3114407C - Anticorps anti-hla-g, compositions comprenant des anticorps anti-hla-g et procedes d'utilisation d'anticorps anti-hla-g - Google Patents

Anticorps anti-hla-g, compositions comprenant des anticorps anti-hla-g et procedes d'utilisation d'anticorps anti-hla-g

Info

Publication number
CA3114407C
CA3114407C CA3114407A CA3114407A CA3114407C CA 3114407 C CA3114407 C CA 3114407C CA 3114407 A CA3114407 A CA 3114407A CA 3114407 A CA3114407 A CA 3114407A CA 3114407 C CA3114407 C CA 3114407C
Authority
CA
Canada
Prior art keywords
sequence
seq
aspects
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3114407A
Other languages
English (en)
Other versions
CA3114407A1 (fr
Inventor
Courtney BEERS
John Corbin
Doug Hodges
Achim Moesta
Vanessa Soros
Paul Fredrick Widboom
Joseph Robert Warfield
Original Assignee
Tizona Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tizona Therapeutics filed Critical Tizona Therapeutics
Priority claimed from PCT/US2019/053158 external-priority patent/WO2020069133A1/fr
Publication of CA3114407A1 publication Critical patent/CA3114407A1/fr
Application granted granted Critical
Publication of CA3114407C publication Critical patent/CA3114407C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des anticorps qui se lient de manière sélective à HLA-G et des compositions comprenant les anticorps. L'invention concerne également des méthodes d'utilisation des anticorps, telles que des méthodes diagnostiques et thérapeutiques.
CA3114407A 2018-09-27 2019-09-26 Anticorps anti-hla-g, compositions comprenant des anticorps anti-hla-g et procedes d'utilisation d'anticorps anti-hla-g Active CA3114407C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737666P 2018-09-27 2018-09-27
US62/737,666 2018-09-27
PCT/US2019/053158 WO2020069133A1 (fr) 2018-09-27 2019-09-26 Anticorps anti-hla-g, compositions comprenant des anticorps anti-hla-g et procédés d'utilisation d'anticorps anti-hla-g

Publications (2)

Publication Number Publication Date
CA3114407A1 CA3114407A1 (fr) 2020-04-02
CA3114407C true CA3114407C (fr) 2026-05-05

Family

ID=

Similar Documents

Publication Publication Date Title
US12264199B2 (en) Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
US20250026850A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
US20210107981A1 (en) Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
TWI797100B (zh) 抗-神經纖毛蛋白質(neuropilin)抗原-結合蛋白及其使用方法
JP7335164B2 (ja) 抗tigit抗原結合タンパク質及びその使用方法
CA2939293C (fr) Anticorps anti-sirp-alpha et anticorps bispecifiques de stimulation des macrophages
CN113993894A (zh) 抗tigit抗体
RU2810326C2 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
WO2025054320A1 (fr) Anticorps anti-ackr4, compositions et utilisations associées
EA045983B1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g